AnaptysBio Quarterly Cash Flow Statement
NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
45.95-0.26 (-0.56%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AnaptysBio free cash flow
In the quarter ended Mar 31, 2026, AnaptysBio generated -$25.9 million of operating cash flow and spent $17,000 on capital expenditures. That left free cash flow of -$25.9 million, a free-cash-flow margin of -101.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
AnaptysBio cash flow statement (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -52.88M | 49.61M | 15.11M | -38.63M | -39.33M | -21.78M | -32.85M | -46.66M | -43.94M | -42.21M | -37.31M | -39.84M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 130.00K | -408.00K | 418.00K | -136.00K | 146.00K | -441.00K | 144.00K | 154.00K | 163.00K | 165.00K | 158.00K | 163.00K |
| Stock-Based Compensation | 14.22M | -23.79M | 24.56M | -6.16M | 9.17M | -18.64M | 8.19M | 7.54M | 10.13M | 8.11M | 7.81M | 8.43M |
| Change in Working Capital | -16.32M | -21.25M | -18.20M | -22.57M | -23.50M | -42.84M | 4.77M | 11.08M | -6.74M | 1.34M | -8.50M | 5.31M |
| Operating Cash Flow | -25.92M | 98.00M | -27.36M | -40.24M | -10.70M | -66.67M | -10.09M | -21.32M | -37.25M | -34.35M | -36.47M | -25.41M |
| Capital Expenditures | -17.00K | -1.00K | -12.00K | -39.00K | -35.00K | -263.00K | -35.00K | -33.00K | -27.00K | -280.00K | -162.00K | -190.00K |
| Investing Cash Flow | 34.98M | 73.50M | 47.58M | 92.11M | 14.85M | -93.43M | 58.62M | -2.44M | 68.62M | 49.18M | 30.64M | -20.45M |
| Share Repurchases | 0 | -3.38M | -9.72M | -51.10M | -4.42M | -456.00K | 0 | 0 | 0 | 0 | 0 | -12.47M |
| Financing Cash Flow | 1.21M | -43.13M | -10.39M | -50.50M | -28.59M | 27.57M | 71.23M | 41.89M | -13.63M | -5.16M | -3.07M | -13.49M |
| Net Change in Cash | 10.27M | 128.36M | 9.83M | 1.36M | -24.44M | -132.54M | 119.76M | 18.13M | 17.73M | 9.67M | -8.91M | -59.36M |
| Free Cash Flow | -25.94M | 98.00M | -27.37M | -40.28M | -10.73M | -66.94M | -10.13M | -21.36M | -37.28M | -34.63M | -36.64M | -25.60M |
This table shows 12 quarterly periods of AnaptysBio's cash flow statement, from Q1 2026 back to Q2 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ANAB's reporting calendar. What is a cash flow statement?